Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Operating Leases (2022 - 2025)

Corvus Pharmaceuticals has reported Operating Leases over the past 4 years, most recently at $632000.0 for Q3 2025.

  • Quarterly results put Operating Leases at $632000.0 for Q3 2025, up 78.53% from a year ago — trailing twelve months through Sep 2025 was $632000.0 (up 78.53% YoY), and the annual figure for FY2024 was $937000.0, down 31.8%.
  • Operating Leases for Q3 2025 was $632000.0 at Corvus Pharmaceuticals, down from $728000.0 in the prior quarter.
  • Over the last five years, Operating Leases for CRVS hit a ceiling of $2.3 million in Q1 2022 and a floor of $354000.0 in Q3 2023.
  • Median Operating Leases over the past 4 years was $937000.0 (2024), compared with a mean of $1.1 million.
  • Biggest five-year swings in Operating Leases: crashed 79.04% in 2023 and later surged 78.53% in 2025.
  • Corvus Pharmaceuticals' Operating Leases stood at $1.4 million in 2022, then grew by 0.07% to $1.4 million in 2023, then tumbled by 31.8% to $937000.0 in 2024, then crashed by 32.55% to $632000.0 in 2025.
  • The last three reported values for Operating Leases were $632000.0 (Q3 2025), $728000.0 (Q2 2025), and $834000.0 (Q1 2025) per Business Quant data.